Based on this background, this study hypothesizes that polymorphisms in OPRM1 and OPRD1 influence the response to opioids, thereby conditioning their therapeutic effectiveness and toxicity in patients with advanced-stage colorectal cancer. This evidence concerns the gene OPRD1 and colorectal cancer.